ADDF Releases SpeechDx Dataset to Advance AI-Powered Alzheimer's Detection Through Speech Biomarkers
核心洞察
The Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator released the first tranche of its SpeechDx dataset, the world's largest harmonized longitudinal collection of speech and biomarker data from Alzheimer's patients.
Paris-based AI company Callyope (搜索) became the second partner to license the dataset, joining Siemens Healthineers in developing speech-based diagnostic tools that can analyze 30 seconds of speech to detect cognitive decline.
The initiative aims to create accessible screening tools using everyday devices like smartphones, potentially revolutionizing early Alzheimer's detection before symptoms appear.
The Alzheimer's Drug Discovery Foundation's (ADDF) Diagnostics Accelerator announced the release of its first SpeechDx dataset and a new partnership with Callyope (搜索), marking significant progress in developing AI-powered tools for early Alzheimer's detection through speech analysis. The initiative represents a major advancement in the quest to identify cognitive decline before clinical symptoms manifest.
Revolutionary Dataset for Early Detection
Launched in 2023, SpeechDx represents a first-of-its-kind initiative to build the world's largest harmonized longitudinal dataset of speech and biomarker data in Alzheimer's and pre-Alzheimer's patients. The newly released data provides researchers with a powerful foundation to develop and validate next-generation diagnostic tools that can detect subtle changes in speech patterns.
"By harnessing AI, we will be able to predict who will develop Alzheimer's and when, unlocking the potential for personalized preventive care on a scale once unimaginable," said Howard Fillit, MD, Co-Founder and Chief Science Officer of the ADDF. "Just as cholesterol tests transformed heart disease prevention, speech and digital biomarkers will revolutionize how we detect, track, and ultimately stop Alzheimer's in its tracks."
The complete dataset will include three years of speech, clinical, and biomarker data from up to 2,000 participants. This comprehensive resource addresses a critical gap in the emerging field of speech-based biomarkers, where subtle changes in speech are increasingly recognized as some of the earliest indicators of cognitive decline.
Callyope Partnership Expands AI Capabilities
Callyope (搜索), a Paris-based AI healthtech company founded in 2023, became the second partner to license the SpeechDx dataset, joining Siemens Healthineers in the growing ecosystem dedicated to advancing speech-based diagnostics. The company will leverage the data to strengthen their AI speech-foundation model, which can analyze just 30 seconds of speech to detect mood, cognitive, psychotic, and motor symptoms across mental health and neurodegenerative disorders including Alzheimer's and Parkinson's.
"The SpeechDx dataset is a gold-standard resource that will allow us to train and validate our AI models on high-quality, ethically sourced longitudinal data," said Martin Denais, Co-Founder and CEO of Callyope (搜索). "At Callyope, our vision is to make brain health monitoring objective, accessible, and transdiagnostic – and to deliver our technologies directly to clinicians through our platform, Callyope Copilot."
Callyope (搜索) has already built what it claims is the world's largest neuroscience speech dataset and is currently validating its speech-based remote patient monitoring platform in 8 clinical trials involving 3,000 controls and 1,000 patients with major depression, bipolar disorders, or schizophrenia.
Accessible Screening Through Everyday Technology
The SpeechDx initiative's potential lies in its accessibility. Because speech can be captured quickly and inexpensively using microphones built into everyday devices like smartphones and computers, the platform lays the groundwork for far more accessible and scalable screening and risk prediction for Alzheimer's and related conditions.
"The release of SpeechDx's first dataset and the addition of Callyope (搜索) as a partner demonstrate the momentum building around this platform," said Niranjan Bose, Managing Director, Health and Life Sciences at Gates Ventures (搜索). "By combining rich, longitudinal speech data with advanced AI, we're opening up new possibilities for earlier detection, progression monitoring, and ultimately more effective intervention in Alzheimer's disease."
Significant Research Investment
The Diagnostics Accelerator, created in July 2018, represents a $100 million global research initiative supported by prominent partners including ADDF Co-Founder Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, and the Charles and Helen Schwab Foundation. The program is dedicated to accelerating the development of affordable and accessible biomarkers to diagnose Alzheimer's disease and related dementias.
The ADDF has previously played pivotal roles in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD (搜索)®) to market. Through donor support, the foundation has awarded more than $370 million to fund 765 Alzheimer's drug development, biomarker, and prevention programs across 21 countries since its founding in 1998.